Belinda Yen-Lieberman

Learn More
  • Devery Howerton, L Thomas, Hearn, Ida M Onorato, M Bernard, Naomi Branson +21 others
  • 2003
Purpose This document provides guidance on quality assurance (QA) practices for sites using or planning to use the OraQuick ® Rapid HIV-1 Antibody Test to detect antibodies to the human immunodeficiency virus (HIV). Background The OraQuick Rapid HIV-1 Antibody Test is the first rapid HIV point-of-care (i.e., testing and results are available in one visit)(More)
conducted a cross-sectional study of β-herpes-viruses in febrile pediatric oncology patients (n = 30), with a reference group of febrile pediatric solid-organ transplant recipients (n = 9). One (3.3%) of 30 cancer patients and 3 (33%) of 9 organ recipients were PCR positive for cyto-megalovirus. Four (13%) of 30 cancer patients and 3 (33%) of 9 transplant(More)
times higher than in those from patients with no history of treatment. However, the prevalence of monore-sistant strains was low (5.3%, 4.3%, 0.3%, and 4.3% for isoniazid, rifampicin, ethambutol, and strepto-mycin, respectively) compared with the prevalence of multidrug-resistant strains whose rate reached a peak of 30.4%. Drug-resistant TB in countries(More)
  • 1